AU2019369397B2 - Compositions and methods comprising IgA antibody constructs - Google Patents

Compositions and methods comprising IgA antibody constructs

Info

Publication number
AU2019369397B2
AU2019369397B2 AU2019369397A AU2019369397A AU2019369397B2 AU 2019369397 B2 AU2019369397 B2 AU 2019369397B2 AU 2019369397 A AU2019369397 A AU 2019369397A AU 2019369397 A AU2019369397 A AU 2019369397A AU 2019369397 B2 AU2019369397 B2 AU 2019369397B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
heavy chain
domain
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019369397A
Other languages
English (en)
Other versions
AU2019369397A1 (en
Inventor
Mark De Boer
Jeannette Henrica Wilhelmina LEUSEN
Geert Jan VAN TETERING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
TigaTx Inc
Original Assignee
UMC Utrecht Holding BV
TigaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV, TigaTx Inc filed Critical UMC Utrecht Holding BV
Publication of AU2019369397A1 publication Critical patent/AU2019369397A1/en
Application granted granted Critical
Publication of AU2019369397B2 publication Critical patent/AU2019369397B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019369397A 2018-10-29 2019-10-29 Compositions and methods comprising IgA antibody constructs Active AU2019369397B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18203183 2018-10-29
EP18203183.1 2018-10-29
US201862752641P 2018-10-30 2018-10-30
US62/752,641 2018-10-30
PCT/US2019/058648 WO2020092427A1 (en) 2018-10-29 2019-10-29 COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

Publications (2)

Publication Number Publication Date
AU2019369397A1 AU2019369397A1 (en) 2021-05-27
AU2019369397B2 true AU2019369397B2 (en) 2026-07-23

Family

ID=70462698

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019369397A Active AU2019369397B2 (en) 2018-10-29 2019-10-29 Compositions and methods comprising IgA antibody constructs

Country Status (9)

Country Link
US (1) US20210332131A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873942A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022506761A (cg-RX-API-DMAC7.html)
KR (1) KR20210096612A (cg-RX-API-DMAC7.html)
CN (1) CN113260632A (cg-RX-API-DMAC7.html)
AU (1) AU2019369397B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118312A1 (cg-RX-API-DMAC7.html)
GB (1) GB2596411B (cg-RX-API-DMAC7.html)
WO (1) WO2020092427A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3131705A1 (en) * 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
CA3187850A1 (en) 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
JP2023546679A (ja) * 2020-10-22 2023-11-07 アクティニウム ファーマシューティカルズ インコーポレイテッド がん治療における放射免疫療法とcd47遮断の併用
CN116829698A (zh) * 2020-12-07 2023-09-29 加利福尼亚大学董事会 通过SIRP-α衔接体的先天免疫细胞沉默
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”
EP4475886A4 (en) * 2022-02-09 2026-03-18 Exelixis Inc MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024021A1 (en) * 2014-08-15 2016-02-18 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
WO2013087914A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
AU2014374055B2 (en) * 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
EP3188758B1 (en) * 2014-08-08 2023-10-04 The Board of Trustees of the Leland Stanford Junior University Sirp alpha-antibody fusion proteins
US9650441B2 (en) * 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
CA3035427A1 (en) * 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Cd20 antibodies
KR102607101B1 (ko) * 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
WO2019022600A1 (en) * 2017-07-24 2019-01-31 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47
AU2018314765C1 (en) * 2017-08-08 2025-11-20 Bruker Spatial Biology, Inc. Obinutuzumab treatment of a DLBCL patient subgroup

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024021A1 (en) * 2014-08-15 2016-02-18 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins

Also Published As

Publication number Publication date
GB2596411B (en) 2023-09-20
CA3118312A1 (en) 2020-05-07
EP3873942A4 (en) 2022-12-28
KR20210096612A (ko) 2021-08-05
GB202107478D0 (en) 2021-07-07
JP2022506761A (ja) 2022-01-17
EP3873942A1 (en) 2021-09-08
AU2019369397A1 (en) 2021-05-27
US20210332131A1 (en) 2021-10-28
GB2596411A (en) 2021-12-29
WO2020092427A1 (en) 2020-05-07
JP2024170456A (ja) 2024-12-10
CN113260632A (zh) 2021-08-13